---
figid: PMC3821079__TOMCJ-7-23_F4
figtitle: The PI3K/AKT pathway is frequently activated in human cancers
organisms:
- NA
pmcid: PMC3821079
filename: TOMCJ-7-23_F4.jpg
figlink: /pmc/articles/PMC3821079/figure/F4/
number: F4
caption: The PI3K/AKT pathway is frequently activated in human cancers. A variety
  of signals including growth factors and nutrients leads to the pathway activation.
  LY294002 and wortmannin are the best characterized PI3Ks inhibitors which prevent
  ATP to bind to and activate PI3Ks []. Both LY294002 and wortmannin induce apoptosis
  in cancer cells and rescue drug sensitivity. Both inhibitors are low molecular weight
  compounds and are also cell-permeable. Wortmannin is a natural metabolite and inhibits
  all class PI3Ks members with a 50% inhibitory concentration (IC50) of 2-5 nM. LY294002
  is a flavonoid-based synthetic compound and inhibits PI3Ks with an IC50 of 1-20
  μM []. LY294002 blocks not only PI3Ks activity but also mTOR to the same extent
  as PI3Ks. Both wortmannin and LY294002 bind to the p110 catalytic subunit of PI3Ks,
  leading to the blockade of ATP bound to the active portion. PI3K inhibition with
  LY294002 is reversible, while wortmannin irreversibly inhibits PI3Ks [,]. Several
  other PI3K inhibitors have been discovered to affect proliferation and survival
  of cancer cells []. Perifosine is a water soluble synthetic alkylphosphocholine
  with oral bioavailability, which inhibits AKT phosphorylation through interaction
  with the PH domain of AKT, resulting in disruption of its PH domain-dependent localization
  to the cell membrane [] (Fig. ). Perifosine reduces cell proliferation and induces
  apoptosis accompanied by AKT dephosphorylation in a wide variety of cancers [].
  Perifosine also targets the MER/ERK 1/2 pro-survival pathway and activated pro-apoptotic
  JNK. PI-103 is a synthesized PI3K inhibitor of pyridofuropyrimidine, which synergistically
  sensitizes leukemia stem cells to daunorubicin-induced cytotoxicity []. Furthermore,
  PI-103 enhances arsenic trioxide cytotoxicity in a heat shock factor 1-dependent
  manner []. KP372-1, an AKT inhibitor, can induce apoptosis in primary leukemic cells
  and cell lines without affecting the survival of normal hematopoietic progenitors
  []. KP372-1 directly inhibited the kinase activity of AKT and PDK1 in a concentration-dependent
  manner. Furthermore, KP372-1 decreased the phosphorylation of the S6 ribosomal (Ser240/244)
  protein []. The mTOR inhibitors are the most developed class of compounds which
  include rapamycin and its derivatives, which bind to FK506 binding protein 12 (FKBP12)
  []. The rapamycin/FKBP12 complex then binds mTORC1 and inhibits downstream signaling
  []. Rapamycin cytotoxicity could be intensely increased by co-treatment with etoposide
  []. Treatment of HL60 cells with phosphatidylinositol ether lipid analogs, a PKB
  inhibitor, also results in inhibition of proliferation and sensitization to chemotherapeutic
  agents []. ATP-competitive mTOR inhibitors have been generated that inhibit the
  activity of both mTORC1 and mTORC2 []. Compared with rapamycin, the mTORC 1/2 inhibitor
  PP242 more efficiently reduces the development of leukemia in mice []. Combining
  the PI3K/PDK1 inhibitor BAG956 with RAD001 also results in a synergistic reduction
  in tumor growth []. PKI-587, a class I PI3Ks inhibitor suppresses phosphorylation
  of PI3K/AKT/mTOR effectors and induces apoptosis in cancer cells []. NVP-BEZ235,
  an orally bioavailable imidazoquinoline derivative that inhibits the activity of
  both PI3K and mTOR by binding to their ATP-binding pocket, reduces proliferation
  and survival in leukemic cell lines without affecting normal hematopoietic progenitors
  [] (Fig. ). However, the administration of PI3K/AKT/mTOR inhibitors can give rise
  to a potentially life-threatening adverse effect such as pneumonitis and so on [].
papertitle: Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy.
reftext: Satoru Matsuda, et al. Open Med Chem J. 2013;7:23-29.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7222614
figid_alias: PMC3821079__F4
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC3821079__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3821079__TOMCJ-7-23_F4.html
  '@type': Dataset
  description: The PI3K/AKT pathway is frequently activated in human cancers. A variety
    of signals including growth factors and nutrients leads to the pathway activation.
    LY294002 and wortmannin are the best characterized PI3Ks inhibitors which prevent
    ATP to bind to and activate PI3Ks []. Both LY294002 and wortmannin induce apoptosis
    in cancer cells and rescue drug sensitivity. Both inhibitors are low molecular
    weight compounds and are also cell-permeable. Wortmannin is a natural metabolite
    and inhibits all class PI3Ks members with a 50% inhibitory concentration (IC50)
    of 2-5 nM. LY294002 is a flavonoid-based synthetic compound and inhibits PI3Ks
    with an IC50 of 1-20 μM []. LY294002 blocks not only PI3Ks activity but also mTOR
    to the same extent as PI3Ks. Both wortmannin and LY294002 bind to the p110 catalytic
    subunit of PI3Ks, leading to the blockade of ATP bound to the active portion.
    PI3K inhibition with LY294002 is reversible, while wortmannin irreversibly inhibits
    PI3Ks [,]. Several other PI3K inhibitors have been discovered to affect proliferation
    and survival of cancer cells []. Perifosine is a water soluble synthetic alkylphosphocholine
    with oral bioavailability, which inhibits AKT phosphorylation through interaction
    with the PH domain of AKT, resulting in disruption of its PH domain-dependent
    localization to the cell membrane [] (Fig. ). Perifosine reduces cell proliferation
    and induces apoptosis accompanied by AKT dephosphorylation in a wide variety of
    cancers []. Perifosine also targets the MER/ERK 1/2 pro-survival pathway and activated
    pro-apoptotic JNK. PI-103 is a synthesized PI3K inhibitor of pyridofuropyrimidine,
    which synergistically sensitizes leukemia stem cells to daunorubicin-induced cytotoxicity
    []. Furthermore, PI-103 enhances arsenic trioxide cytotoxicity in a heat shock
    factor 1-dependent manner []. KP372-1, an AKT inhibitor, can induce apoptosis
    in primary leukemic cells and cell lines without affecting the survival of normal
    hematopoietic progenitors []. KP372-1 directly inhibited the kinase activity of
    AKT and PDK1 in a concentration-dependent manner. Furthermore, KP372-1 decreased
    the phosphorylation of the S6 ribosomal (Ser240/244) protein []. The mTOR inhibitors
    are the most developed class of compounds which include rapamycin and its derivatives,
    which bind to FK506 binding protein 12 (FKBP12) []. The rapamycin/FKBP12 complex
    then binds mTORC1 and inhibits downstream signaling []. Rapamycin cytotoxicity
    could be intensely increased by co-treatment with etoposide []. Treatment of HL60
    cells with phosphatidylinositol ether lipid analogs, a PKB inhibitor, also results
    in inhibition of proliferation and sensitization to chemotherapeutic agents [].
    ATP-competitive mTOR inhibitors have been generated that inhibit the activity
    of both mTORC1 and mTORC2 []. Compared with rapamycin, the mTORC 1/2 inhibitor
    PP242 more efficiently reduces the development of leukemia in mice []. Combining
    the PI3K/PDK1 inhibitor BAG956 with RAD001 also results in a synergistic reduction
    in tumor growth []. PKI-587, a class I PI3Ks inhibitor suppresses phosphorylation
    of PI3K/AKT/mTOR effectors and induces apoptosis in cancer cells []. NVP-BEZ235,
    an orally bioavailable imidazoquinoline derivative that inhibits the activity
    of both PI3K and mTOR by binding to their ATP-binding pocket, reduces proliferation
    and survival in leukemic cell lines without affecting normal hematopoietic progenitors
    [] (Fig. ). However, the administration of PI3K/AKT/mTOR inhibitors can give rise
    to a potentially life-threatening adverse effect such as pneumonitis and so on
    [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mtor
  - Tor
  - Pten
  - Akt
  - pk
  - MTOR
  - PTEN
  - AKT1
  - AKT2
  - AKT3
---
